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Sound Healthcare System were eligible. Presence of a clonal
IgH rearrangement, t(11;14) by PCR or positive ﬂow cytom-
etry from blood or bone marrow prior to transplant was
scored as MRD positive. MRD along with clinical factors were
evaluated in an adjusted proportional hazards model for
associations with progression-free (PFS) and overall survival
(OS).
Results: Seventy-ﬁve transplanted MCL patients in CR had
pretransplant MRD evaluation performed. The median age
was 58 years (range, 38-71), 59 (78.7%) were men, the me-
dian number of prior regimens was 1 (range 1-4), and the
median MIPI score was 2 (range 0-7). Induction chemo-
therapy consisted of HyperCVAD in 37 (49.3%), CHOP in 36
(48%), CVP in 1(1.3%), and Cytoxan in 1 (1.3%). Rituximabwas
administered to 63 (84%) as part of their pretransplant
regimen. Eight patients (11%) had evidence of MRD. Positive
MRD tests included: t(11:14) only in 4 (50%), ﬂow only in 2
(25%), and ﬂow and t(11;14) PCR positive in 2 (25%). Sites of
MRD included bone marrow in 5 (62.5%) and peripheral
blood in 4 (50%). MRD positivity was highly associated with
both OS and PFS in unadjusted and adjusted models (Figure
1). With a median follow-up of survivors of 5.1 years, the
median OS for MRD negative patients was not reached,
while for the MRD positive patients was 3.01 years (hazard
ratio [HR] 4.04, p ¼ 0.009). The median PFS for MRD
negative patients was not reached, while for the MRD
positive patients was 2.38 years (HR 3.69, p ¼ 0.002).
Discussion: These data indicate that MRD positivity is
independently associated with poor outcome following ASCT
for MCL patients despite achieving a clinical CR. New treat-
ment strategies such as post-transplant maintenance regi-
mens or reduced intensity allogeneic transplantation could
be evaluated in this setting in an attempt to improve
remission durations and survival.145
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Objective: To compare the outcome of patients with Non-
Hodgkins Lymphoma undergoing autologous peripheral
blood stem cell transplantation (PBSCT) conditioned with
FluBuTBI or BEAM (BCNU, Etoposide, Cytarabine, and
Melphalan) at our institution.
Patients and Methods: We conducted a retrospective anal-
ysis of patients (n¼81) who underwent autologous PBSCT at
our institution and were conditioned with BEAM (n¼40) or
FluBuTBI (n¼41) between January 2006 and January 2013.
Recipients were classiﬁed according to CIBMTR criteria and
those conditioned with BEAM were low risk (n¼14) and in-
termediate risk (n¼26). Recipients conditioned with Flu-
BuTBI were low risk (n¼10), intermediate risk (n¼27) and
high risk (n¼4). Median age of patients in the BEAM group
was 57.2 years compared to 59.6 years for FluBuTBI. At the
time of transplantation, 25 of 40 patients who received
BEAMwere in complete remission (62.5%) compared to 21 of
41 patients (51.2%) for FluBuTBI. Median time of follow up
was 57 months for BEAM and 30.2 months for FluBuTBI.FluBuTBI consisted of intravenous (IV) Fludarabine 50mg/
m2/day infused over 1 hour on days -6 through -2, IV
Busulfan 3.2 mg/kg/day on days -5 through -2 (infusion rate
80 mg/hour) and TBI 200 cGy on days -2 and -1. BEAM
regimen consisted of IV BCNU 300 mg/m2 infused over 1 hr
on day -5, Etoposide 200 mg/m2/day over 3 hours on days -5
through -2, Cytarabine 200 mg/m2/day over 1 hour every 12
hours on days -5 through -2, and Melphalan 140 mg/m2 over
1 hr on day -1. Diagnoses were transformed follicular lym-
phoma (n¼1), composite lymphoma (n¼1), CLL (n¼1),
anaplastic large cell lymphoma (n¼2), B-cell lymphoma NOS
(n¼3), Burkitt’s lymphoma (n¼3), peripheral T-cell lym-
phoma (n¼5), follicular lymphoma (n¼16), mantle cell
lymphoma (n¼23), diffuse large B-cell lymphoma (n¼ 26).
Results: Overall survival (OS) at 3 years for the FluBuTBI
group was 76.2% compared to BEAM at 57.5%. Cumulative
incidence of disease progression at 3 years was 24.5% for
FluBuTBI compared to 45% for BEAM group (p¼0.039).
Relapse related mortality (RRM) at 3 years for FluBUTBI was
8.7% compared to 32.4% for the BEAM group (p¼0.012).
Treatment related mortality was observed in 2.5% (n¼1) in
the BEAM group while none in the FluBuTBI group. Treat-
ment related MDS/AML occurred in 2.4% (n¼1) in FluBUTBI
compared to 7.5% (n¼3) in the BEAM group. Grade 3-4
mucositis was seen in 14.6% (n¼6) in the FluBuTBI group
while not observed in the BEAM group.
Conclusion: Our institutional data showed better OS and less
RRM in the FluBuTBI group compared to BEAM as condi-
tioning regimen for Non-Hodgkins Lymphoma undergoing
Autologous PSCT. This difference was present despite older
and higher risk patients in the FluBuTBI group. Mucositis was
more frequent in the FluBuTBI group. Conditioning with
FluBuTBI is a safe and effective alternative to BEAM for
autologous PBSCT which needs to be validated by random-
ized prospective studies.146
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Background: The use of plerixafor can decrease the number
of apheresis collection days for a given patient, which in turn
reduces cost and other various resources. An algorithm was
developed at our facility based on the paper published by LJ
Costa in 2010 to predict the need for plerixafor on day four of
G-CSF mobilization.
Methods: Peripheral blood is drawn on day four of G-CSF
mobilization (10mg/kg) for CD34 enumeration (pretube) us-
ing the single-platform ISHAGE method. If the value is <14
CD34/mL for a single transplant or <25 CD34/mL for a tandem
transplant the transplant recipient will receive plerixafor
(0.24mg/kg). If a patient does not qualify for plerixafor on the
day previous to apheresis and does not collect all CD34/kg
required on day one they receive plerixafor for day two of
apheresis. This algorithm is used for all autologous transplant
disease types treated at our facility (multiple myeloma, non-
Hodgkin lymphoma, Hodgkin lymphoma, and germ cell) and
is not adjusted for age, gender, performance status, etc.
except under the direction of the medical director. Our tar-
gets for stem cell collection are 3.0x106 CD34/kg for a single
transplant and 6.0x106 CD34/kg for tandem transplants.
Results: From 2007-2009 we had a total of 110 apheresis
collections (38 patients) for a single transplant with an
average of 2.5 collection days per patient using G-CSF alone.
23.7% (n¼9) of our patients collected in one day, 26.3%
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three or more days. There were 28 tandem transplant col-
lections (8 patients) with an average of 2.9 days of apheresis
collection per patient. 12.5% (n¼1) of our patients had one
day of collection, 50% (n¼4) had two days and 37.5% (n¼3)
had three or more days of apheresis. Plerixafor was ﬁrst
given in 01/2009 and until 07/2010 our patients received the
drug based on insurance approval or as a second line of
therapy after collection failure. Our algorithm was imple-
mented starting 03/2011 and to date for a single transplant
we have had 109 collections (67 patients) with an average of
1.7 days of collection per patient. 64% of patients (n¼43)
collected in one day, 25% (n¼17) collected in two days and
10% (n¼7) collected in three or more days. There were 42
tandem transplant collections (30 patients) with an average
of 1.5 days of apheresis collection per patient. 77% (n¼23) of
our patients collected in one day, 16.7% (n¼5) collected in
two days and 7% (n¼2) collected in three or more days (see
Figures 1 and 2). There is a signiﬁcant difference between the
number of collection days needed for patients that received
G-CSF alone and the collection days needed for patients
evaluated with our algorithm (p<0.001).
Conclusion/Summary: The addition of an algorithm for the
use of plerixafor has signiﬁcantly reduced the number of
collections needed per patient, which in turn reduces cost
and resources.147
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High-dose melphalan followed by autologous hematopoietic
cell transplant (AHCT) can improve long-term outcome of
patients with primary amyloidosis. Historically, it has been
associated with high transplant related mortality (TRM).
However, improvement in patient selection has resulted in
decreased TRM and improved outcomes. The most common
approach, if patients are determined to be eligible, is to
proceed directly to ASCT. However, at our institution,
patients uniformly receive bortezomib-based induction
therapy to obtain best response prior to transplant.
We performed a retrospective analysis to evaluate the
outcomes of AL amyloidosis patients undergoing ASCT at our
institution.
From 6/2007 to 3/2014, 24 patients underwent AHCT,
receiving either melphalan 200mg/m2 or 140mg/m2 as a
single dose. The median age at transplant was 60 years
(range 35 to 72), with 54% male patients. Karnofsky Perfor-
mance Status was 80% or higher in 87% of patients. Only 13%
had known cardiac involvement. All patients had normal
troponin levels and the median NT-pro-BNP 253 (range 62 to
7580). Themajority of patients had either intermediate (21%)
or high (47%) risk co-morbidity index scores. The median
time from diagnosis to transplant was 8.3 months, with the
majority of patients receiving at least 1 line of prior therapy
(92%). For disease response, following induction therapy, 58%
were transplanted in ﬁrst complete response (CR) or partial
response (PR), 8% in second PR, and 33% with refractory
disease. Patients were mobilized with either G-CSF alone
(79%), G-CSF + plerixafor (17%), or G-CSF + cyclophosphamide
